- Understanding the Role of Adalimumab in the Treatment of Moderately to Severely Active Ulcerative Colitis
-
Kim JH, Cheon JH
- KMID: 2363960
- Gut Liver.
- 2016 Mar;10(2):162-163.
- doi: 10.5009/gnl16024
No abstract available. -
- CITED
-
- Close
- SHARE
-
- Close
- Golimumab Therapy in Ulcerative Colitis
-
Moon W
- KMID: 2383543
- Korean J Gastroenterol.
- 2016 Feb;67(2):64-73.
- doi: 10.4166/kjg.2016.67.2.64
Ulcerative colitis is a chronic inflammatory condition of the colon, characterized by diffuse mucosal inflammation and blood-mixed diarrhea. The main treatment has been 5-aminosalicylic acid, steroid, thiopurine, and anti-tumor necrosis... -
- CITED
-
- Close
- SHARE
-
- Close
- A Perspective: Role of Targeted Therapy in Colon Cancer
-
Chung HH, Jang BI
- KMID: 1501635
- Korean J Gastroenterol.
- 2013 Mar;61(3):128-135.
- doi: 10.4166/kjg.2013.61.3.128
Colorectal cancer is the third most common malignant disease in incidence according to a report in 2009 from Korea. The 5-fluorouracil (5-FU) remains to be a major chemotherapeutic agents. But,... -
- CITED
-
- Close
- SHARE
-
- Close
- Current and Emerging Biologics for Ulcerative Colitis
-
Park SC, Jeen YT
- KMID: 2380778
- Gut Liver.
- 2015 Jan;9(1):18-27.
- doi: 10.5009/gnl14226
Conventional medical treatment for ulcerative colitis can have limited efficacy or severe adverse reactions requiring additional treatment or colectomy. Hence, different biological agents that target specific immunological pathways are being... -
- CITED
-
- Close
- SHARE
-
- Close
- Update on immune checkpoint inhibitors in gynecological cancers
-
Heong V, Ngoi N, Tan DS
- KMID: 2413459
- J Gynecol Oncol.
- 2017 Mar;28(2):e20.
- doi: 10.3802/jgo.2017.28.e20
In recent years, progress in our understanding of immune-modulatory signaling pathways in immune cells and the tumor microenvironment (TME) has led to rejuvenated interest in cancer immunotherapy. In particular, immunotherapy... -
- CITED
-
- Close
- SHARE
-
- Close
- Angiographically Documented Macular Ischemia after Single Bevacizumab for Macular Edema Secondary to Central Retinal Vein Occlusion
-
Lee KH, Kang EC, Koh HJ
- KMID: 2419132
- Yonsei Med J.
- 2017 May;58(3):676-678.
- doi: 10.3349/ymj.2017.58.3.676
This report describes a case of angiographically documented foveal avascular zone (FAZ) enlargement after a single intravitreal injection of bevacizumab for macular edema secondary to central retinal vein occlusion (CRVO).... -
- CITED
-
- Close
- SHARE
-
- Close
- Drug Survival Rates of Tumor Necrosis Factor Inhibitors in Patients with Rheumatoid Arthritis and Ankylosing Spondylitis
-
Kang JH, Park DJ, Lee JW, Lee KE, Wen L, Kim TJ, Park YW, Lee SS
- KMID: 1794597
- J Korean Med Sci.
- 2014 Sep;29(9):1205-1211.
- doi: 10.3346/jkms.2014.29.9.1205
We investigated the compliance of Korean patients using tumor necrosis factor (TNF) inhibitors to treat rheumatoid arthritis (RA) and ankylosing spondylitis (AS), and identified potential predictors associated with treatment discontinuation.... -
- CITED
-
- Close
- SHARE
-
- Close
- Patients with Arthritis Undergoing Surgery: How Should We Manage Tumour Necrosis Factor Blocking Agents Perioperatively?: A Systematic Literature Review
-
Pieringer , Danninger , Tzaribachev N, Bohler N, Pohanka E, Herold M
- KMID: 1776947
- Yonsei Med J.
- 2013 Jan;54(1):253-257.
- doi: 10.3349/ymj.2013.54.1.253
We systematically reviewed the literature on the infectious risk in patients treated with tumour necrosis factor blocking agents (TNF-BA) undergoing surgery: we searched the Medline (PubMed) and the online archive... -
- CITED
-
- Close
- SHARE
-
- Close
- Predictive Factors of Mortality in Population of Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH): Results from a Korean PNH Registry
-
Jang JH, Kim JS, Yoon SS, Lee JH, Kim YK, Jo DY, Chung J, Sohn SK, Lee JW
- KMID: 2360045
- J Korean Med Sci.
- 2016 Feb;31(2):214-221.
- doi: 10.3346/jkms.2016.31.2.214
Paroxysmal nocturnal hemoglobinuria (PNH) is a progressive, systemic, life-threatening disease, characterized by chronic uncontrolled complement activation. A retrospective analysis of 301 Korean PNH patients who had not received eculizumab was... -
- CITED
-
- Close
- SHARE
-
- Close
- Factors Contributing to the Preference of Korean Patients with Crohn's Disease When Selecting an Anti-Tumor Necrosis Factor Agent (CHOICE Study)
-
Kim ES, Kim KO, Jang BI, Lee CK, Kim HJ, Lee KM, Kim YS, Eun CS, Jung SA, Yang SK, Lee J, Kim TO, Jung Y, Seo GS, Yoon SM, the IBD Study Group of the Korean Association for the Study of the Intestinal Diseases (KASID)
- KMID: 2411966
- Gut Liver.
- 2016 May;10(3):391-398.
- doi: 10.5009/gnl15126
BACKGROUND/AIMS: Two comparable anti-tumor necrosis factor (TNF) agents with different routes of administration (intravenous [iv] infliximab [IFX] vs subcutaneous [sc] adalimumab [ADA]) are available for patients with Crohn's disease (CD)... -
- CITED
-
- Close
- SHARE
-
- Close
- Pegylated Interferon-Associated Severe Retinopathy in a Patient with Chronic Hepatitis
-
Kang HY, Shin MC
- KMID: 1364871
- Korean J Ophthalmol.
- 2012 Apr;26(2):147-150.
- doi: 10.3341/kjo.2012.26.2.147
This paper reports a case of pegylated interferon-associated retinopathy in a patient with chronic hepatitis C. A 32-year-old female with chronic hepatitis C undergoing pegylated interferon and ribavirin combination therapy... -
- CITED
-
- Close
- SHARE
-
- Close
